What INNOVENTRIC does

Innoventric Ltd. is a privately held Israeli medical device company founded in 2016/2017 in the Ness-Ziona/Rehovot area, developing transcatheter systems to treat tricuspid regurgitation (TR). The company's core innovation is a cross-caval heterotopic approach that deploys valve implants in the superior and inferior vena cava (SVC and IVC) rather than replacing or repairing the tricuspid valve itself, enabling treatment of patients with severe or torrential TR who are ineligible for transcatheter edge-to-edge repair (TEER), orthotopic transcatheter tricuspid valve replacement (TTVR), or bi-caval valve replacement. The portfolio comprises three devices: Trillium™, a multi-valve device with a flexible hinge design optimized for large and tortuous anatomies; Koala™, a cross-caval docking station for anchoring off-the-shelf valves in the SVC and IVC; and Unica™, an anatomy-agnostic single-stent, double-valve implant on a 26 Fr delivery system designed for venous transfemoral access, sub-10-minute device time, conscious sedation compatibility (no TEE or general anesthesia required), and future valve-in-valve or transseptal re-intervention. Reported technical performance includes 600M-cycle durability testing with no fractures, migration-resistant anchoring, and immediate hemodynamic improvements (V-wave CVP reduction of 12 mmHg and cardiac output increase from 6 to 9.6 L/min in first US EFS case).

Innoventric's business model is clinical-stage hardware sales delivered through FDA-approved IDE Early Feasibility Studies, compassionate use programs, and First-in-Human clinical investigations. Distribution is direct to interventional cardiology departments at leading cardiac centers across the US, Germany, Belgium, Spain, Israel, Canada, France, Italy, and Georgia, with go-to-market executed via clinical investigator engagement and medical conference dissemination rather than conventional field sales. Pricing is not publicly disclosed; the company has recognized no commercial revenue to date, with funding of approximately $48M cumulatively sourced from a €2.5M Horizon Europe grant (Nov 2021), a $14M Series A (Nov 2021), and a $28.5M Series B (Oct 2024, led by RA Capital Management). The company holds over 50 granted cardiovascular patents and is led by founder/CEO Amir Danino (inventor of the technology) and co-founders Rafi Benary (previously founded Ventor Technologies, acquired by Medtronic in 2009) and Dr. David Planer (Head of Interventional Cardiology at Hadassah Medical Center).

The served customer base is concentrated in academic and high-volume cardiac centers performing structural heart interventions, with named clinical collaborators including TriStar Centennial Medical Center (Nashville), St. Michael's Hospital Toronto, Hadassah Medical Center, Leipzig Heart Center, and Hospital Alvaro Cunqueiro (Vigo). Customer segments are the patients with tricuspid regurgitation previously deemed untreatable by other interventional therapies, and the interventional cardiology centers seeking an anatomy-agnostic TR solution compatible with conscious sedation and short procedure times. Regulatory milestones include FDA IDE approval for the Trillium EFS (December 2023), completion of European/Israeli FIH enrollment at 20 patients with 2.5-year follow-up (July 2023), and completion of 15-patient US/German EFS enrollment (September 2025), with extended enrollment announced November 2025.

Name

INNOVENTRIC

Legal name

Innoventric Ltd.

Website

https://innoventric.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Innoventric is a Rehovot, Israel-based clinical-stage medical device company developing transcatheter cross-caval heterotopic valve implants (Trillium, Koala, Unica) to treat tricuspid regurgitation in patients ineligible for TEER or orthotopic TTVR, currently delivering devices through FDA IDE Early Feasibility Studies and compassionate use programs at leading cardiac centers across the US, Europe, Israel, and Canada.

Ownership category

akta.pro rank

Product category

Transcatheter Heart Valve Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industry

Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)

Keywords

• Transcatheter valve replacement
• Tricuspid regurgitation treatment
• Structural heart devices
• Catheter-delivered implants
• Interventional cardiology devices

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Medical Device Sales: Revenue generated from sale of transcatheter valve replacement devices (Trillium, Koala, Unica) to hospitals and cardiac centers. Currently available through clinical trials and compassionate use programs. Future commercial launch will expand direct hospital sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Innoventric designs, develops, and manufactures transcatheter tricuspid regurgitation (TR) treatment devices using a proprietary cross-caval heterotopic approach. The company sells three flagship implant systems — Trillium™, Koala™, and Unica™ — to interventional cardiology departments at hospitals and cardiac centers, currently delivered through clinical trials and compassionate use programs ahead of broader commercial launch.

Product overview

Innoventric develops transcatheter tricuspid regurgitation (TR) solutions using a cross-caval heterotopic approach. The company's portfolio includes three core devices: Trillium™ (the first cross-caval device with multiple valves and novel hinge design for large/tortuous anatomies), Koala™ (a docking station for anchoring off-the-shelf valves in SVC and IVC), and Unica™ (an anatomy-agnostic implant with bare metal structure and intra-luminal valves for broader patient population including smaller anatomies). All devices employ a heterotopic approach that targets the caval system rather than the valve itself, enabling treatment of patients previously considered untreatable. The Unica™ features a 26 Fr low-profile delivery system and is designed for less than 10 minutes device implantation time with conscious sedation, eliminating the need for TEE or general anesthesia.

Differentiator

Problem solved

Functional benefit

Brands

• Trillium: First-of-its-kind cross-caval device for treating tricuspid regurgitation (TR) in a broad patient population. Features multiple valves with a novel hinge design, beneficial for large and tortuous anatomies.
• Koala
• Unica

Products and services

• Trillium™ First-of-its-kind cross-caval transcatheter device for tricuspid regurgitation, featuring multiple valves with a novel hinge design and intended for a broad patient population, including those with large and tortuous anatomies. Device implantation time is under 10 minutes, with secure migration-resistant positioning and reliable sealing.
• Koala™ Cross-caval docking station designed to anchor in both the SVC and IVC and facilitate placement of an off-the-shelf valve for tricuspid regurgitation treatment. Several compassionate cases have been performed in the EU.
• Unica™ Anatomy-agnostic single-stent, double-valve heterotopic cross-caval implant for safe and effective TR treatment, extending care to a broader patient population including those with smaller anatomies. Features a bare-metal center structure enabling future transseptal procedures and intra-luminal valves supporting future valve-in-valve procedures, secured to SVC and IVC with migration-resistant anchoring. Delivered via a 26 Fr low-profile venous transfemoral system under conscious sedation without TEE or general anesthesia. Compassionate use cases performed in the EU and Canada.

Quantifiable outcome

• Cardiac output increase from 6 L/min to 9.6 L/min observed in first US EFS patient
• +5 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Edwards Lifesciences: Global structural heart leader with PASCAL transcatheter tricuspid repair and Evoque TTVR programs. Directly competes in TR with multiple modalities and vastly larger commercial infrastructure.
• Medtronic: Acquired Ventor Technologies (founded by Innoventric co-founder Rafi Benary) in 2009 and has a long-standing structural heart presence. A natural strategic acquirer of transcatheter valve innovation.
• Abbott: Markets TriClip, the first FDA-approved transcatheter tricuspid TEER device, and is developing orthotopic TTVR options. Competes with Innoventric for the same patient population and cardiology KOL relationships.

Emerging players

• Cardiac Dimensions: Developer of the Carillon System for tricuspid and mitral functional regurgitation via coronary sinus annuloplasty. Competes with Innoventric in the transcatheter TR treatment market with a different mechanism.
• Polares Medical: Spin-off from Halfmoon Medical (acquired by Edwards Lifesciences) developing a transcatheter tricuspid valve replacement technology. Direct overlap with Innoventric in orthotopic-style TR replacement.
• Anteris Technologies: Structural heart company developing the DurAVR transcatheter heart valve system with proprietary 3D-shaped valve technology. Comparable as a clinical-stage transcatheter valve developer targeting structural heart indications.
• Cardiovalve: Developed a transcatheter tricuspid and mitral valve replacement system (now part of Venus Medtech). Direct overlap with Innoventric in transcatheter valve replacement for tricuspid regurgitation.
• 4C Medical Technologies: Develops transcatheter mitral and tricuspid valve technologies including AltaValve, an supra-annular system. Competes in the structural heart replacement space adjacent to Innoventric's TR focus.
• CroíValve: Early-stage Irish company developing a transcatheter tricuspid coaptation valve, addressing a similar patient population as Innoventric via a different anchoring mechanism.
• Venus Medtech: Chinese structural heart company that acquired Cardiovalve, a transcatheter tricuspid and mitral valve developer. Competes with Innoventric in transcatheter TR with both repair and replacement approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/innoventric

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INNOVENTRIC